CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles.
about
Inducible Bronchus-Associated Lymphoid Tissue: Taming Inflammation in the LungPotential of Cells and Cytokines/Chemokines to Regulate Tertiary Lymphoid Structures in Human DiseasesEctopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur?The Immunogenetics of Autoimmune CholestasisAssociation of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humansDifferential induction of isolated lymphoid follicles in the gut by 18β-glycyrrhetinic acidImmunoglobulin responses at the mucosal interface.Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphoma18β-glycyrrhetinic acid delivered orally induces isolated lymphoid follicle maturation at the intestinal mucosa and attenuates rotavirus shedding.TNFα-dependent development of lymphoid tissue in the absence of RORγt⁺ lymphoid tissue inducer cells.TLR5 signaling stimulates the innate production of IL-17 and IL-22 by CD3(neg)CD127+ immune cells in spleen and mucosa.Distinct developmental requirements for isolated lymphoid follicle formation in the small and large intestine: RANKL is essential only in the small intestine.Decreased Frequency of Intestinal Regulatory CD5+ B Cells in Colonic Inflammation.Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge.IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs.Migration and Tissue Tropism of Innate Lymphoid Cells.Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis.Novel CXCL13 transgenic mouse: inflammation drives pathogenic effect of CXCL13 in experimental myasthenia gravis.Function of mucosa-associated lymphoid tissue in antibody formation.The biology of chemokines and their receptors.Interleukin-22: a likely target for treatment of autoimmune diseasesManipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment avenue?Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications.Plasticity of neutrophils reveals modulatory capacity.The role of ILC2 in hookworm infection.Lineage relationships of human interleukin-22-producing CD56+ RORγt+ innate lymphoid cells and conventional natural killer cells.Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology.Isolated Lymphoid Follicles are Dynamic Reservoirs for the Induction of Intestinal IgA.The Development of Steady-State Activation Hubs between Adult LTi ILC3s and Primed Macrophages in Small Intestine.IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with Citrobacter rodentium.High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients.The chronicity of tonsillitis is significantly correlated with an increase in an LTi cell portion.A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.
P2860
Q26742160-837959BA-2BDE-403C-8A69-A9E475CC0BE1Q28071670-935138DC-9D9C-4590-BF85-5BB695452DA2Q28077990-294D35C1-CFA5-4A52-8A90-2B4921901173Q28085346-AC942B63-F7EE-4C70-8FFF-9E9228014B21Q30475578-7E63AB56-C881-420D-9AE4-06879058FCFAQ31172569-014D1800-B4B8-49FC-B0E5-B97222BA832AQ34025272-ADA001A2-A897-4E2E-BDE4-74BA8CF678E9Q34454590-E2B30826-5CD9-46B7-B383-24B4C5992C7FQ34478029-96E11FAF-1F3A-477E-8982-890612C4215CQ34690481-04BF05F6-94E7-428D-8FB2-78FCA0E10DB7Q34694834-36D6FB82-C61D-42BF-B5E2-CA537C954AF9Q35235833-F41C4B3C-C2A7-4ED1-A616-B2979636CE02Q35883881-05DAB130-8395-4F0F-BEB6-6DBD03C17DBCQ36031510-06754759-277A-43F0-93F6-EFF0F4C75D91Q36055624-77243F35-7B31-4223-8AD9-217C3E88ACAFQ36554706-ED9D3F15-5030-4B2E-9B7F-F8636F52A291Q36656518-52D64B06-5EFD-44C8-8744-170BFB51EADFQ36946564-D712753D-28C3-495F-A89B-19A09E4334A9Q37744898-D85CB114-771A-41DA-B7B1-6492B060CDABQ37998913-AFB69C91-736E-4147-8339-502ED6E43DC3Q38177958-5E6380A9-1BA2-4258-9FD2-A4E71BD7F1ACQ38201655-D0DDD277-FDA7-4845-B87F-6E04DCFB7B47Q38435397-4CB61790-9E5D-44B5-A5E2-14292C847F90Q38537035-DDAA27A1-A89C-46FF-BDB3-996D00236CBAQ39215742-0D95C773-792C-4D28-AB15-5A0B549A9C16Q39217244-88E30259-2578-48BB-A918-9BADC6774C7AQ41904687-ACE1766F-63D4-4A62-9A21-9635EDE614B6Q41964089-FED265A3-BE38-44AB-8AA3-AD56570394D3Q42145975-EECA2F39-30A1-413F-B090-C20E1120A3CEQ42512933-048576E2-E301-45F8-A739-08A10E61399CQ46485022-6D46F06A-D4E4-4371-9590-DA37DB4436AFQ48107857-3746BB2F-9D4D-4AF4-901B-01BC29B296FBQ50882792-AD53F3A0-7676-40DB-8B0C-AED63326AC83Q55038717-4078CC84-149E-461C-901A-D4452A6C92ED
P2860
CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@ast
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@en
type
label
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@ast
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@en
prefLabel
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@ast
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@en
P2093
P2860
P356
P1433
P1476
CXCL13 expression in the gut p ...... f isolated lymphoid follicles.
@en
P2093
A P Martin
G C Furtado
M G Grisotto
N Thirunarayanan
P2860
P2888
P304
P356
10.1038/MI.2009.113
P577
2009-09-09T00:00:00Z
P5875
P6179
1023834570